Profile data is unavailable for this security.
About the company
Lyell Immunopharma, Inc. is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. The Company is engaged in enrolling a Phase I clinical trial evaluating a ROR1-targeted CAR T-cell therapy in patients with relapsed refractory triple-negative breast cancer and non-small cell lung cancer (NSCLC) and a second Phase I clinical trial evaluating reprogrammed tumor infiltrating lymphocytes (TIL) in patients with advanced melanoma, NSCLC and colorectal cancer. The technologies powering its product candidates are designed to address barriers that limit consistent and long-lasting responses to cell therapy for solid tumors: T-cell exhaustion and lack of durable stemness, which includes the ability to persist and self-renew to drive durable tumor cytotoxicity. The Company is applying its proprietary ex vivo genetic and epigenetic reprogramming technologies to address these barriers in order to develop medicines.
- Revenue in USD (TTM)54.00k
- Net income in USD-210.26m
- Incorporated2018
- Employees224.00
- LocationLyell Immunopharma Inc201 Haskins Way, Suite 301SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 695-0677
- Fax+1 (302) 531-3150
- Websitehttps://lyell.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aldeyra Therapeutics Inc | 0.00 | -37.87m | 349.99m | 10.00 | -- | 3.56 | -- | -- | -0.6387 | -0.6387 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -26.89 | -36.79 | -31.76 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1342 | -- | -- | -- | 39.47 | -- | -- | -- |
Lexeo Therapeutics Inc | 0.00 | -77.22m | 356.40m | 58.00 | -- | 2.16 | -- | -- | -2.81 | -2.81 | 0.00 | 4.99 | 0.00 | -- | -- | 0.00 | -60.10 | -- | -68.82 | -- | -- | -- | -- | -- | -- | -- | 0.0097 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
Inozyme Pharma Inc | 0.00 | -88.56m | 359.47m | 59.00 | -- | 3.77 | -- | -- | -1.46 | -1.46 | 0.00 | 1.52 | 0.00 | -- | -- | 0.00 | -57.76 | -45.00 | -63.48 | -48.90 | -- | -- | -- | -- | -- | -- | 0.3244 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
Jasper Therapeutics Inc | 0.00 | -62.44m | 360.71m | 45.00 | -- | 3.60 | -- | -- | -5.10 | -5.10 | 0.00 | 6.64 | 0.00 | -- | -- | 0.00 | -52.45 | -- | -57.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
AC Immune SA | 18.22m | -71.18m | 365.09m | 133.00 | -- | 2.52 | -- | 20.04 | -0.755 | -0.755 | 0.1968 | 1.46 | 0.0787 | -- | 28.76 | 136,985.20 | -30.73 | -18.25 | -42.90 | -19.52 | -- | -- | -390.68 | -148.29 | -- | -128.01 | 0.0255 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
Nkarta Inc | 0.00 | -107.91m | 367.61m | 150.00 | -- | 0.8112 | -- | -- | -2.01 | -2.01 | 0.00 | 6.42 | 0.00 | -- | -- | 0.00 | -21.95 | -32.39 | -23.07 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
Alto Neuroscience Inc | -100.00bn | -100.00bn | 369.07m | 78.00 | -- | 2.05 | -- | -- | -- | -- | -- | 6.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.053 | -- | -- | -- | -31.02 | -- | -- | -- |
Corvus Pharmaceuticals Inc | 0.00 | -22.62m | 369.68m | 28.00 | -- | 7.22 | -- | -- | -0.4458 | -0.4458 | 0.00 | 0.8189 | 0.00 | -- | -- | 0.00 | -36.89 | -38.31 | -44.60 | -43.34 | -- | -- | -- | -- | -- | -22.18 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
Organogenesis Holdings Inc | 448.39m | -16.54m | 375.19m | 862.00 | -- | 1.42 | -- | 0.8367 | -0.125 | -0.125 | 3.38 | 1.99 | 1.00 | 4.27 | 4.49 | 520,176.30 | -3.70 | 5.46 | -4.51 | 6.90 | 75.14 | 74.94 | -3.69 | 4.81 | 2.42 | 8.33 | 0.2001 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
GH Research PLC | -100.00bn | -100.00bn | 383.97m | 49.00 | -- | 1.93 | -- | -- | -- | -- | -- | 3.82 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0038 | -- | -- | -- | -58.47 | -- | -- | -- |
Nautilus Biotechnology Inc | 0.00 | -69.64m | 386.27m | 164.00 | -- | 1.64 | -- | -- | -0.557 | -0.557 | 0.00 | 1.88 | 0.00 | -- | -- | 0.00 | -23.08 | -- | -23.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
Lyell Immunopharma Inc | 54.00k | -210.26m | 386.56m | 224.00 | -- | 0.6822 | -- | 7,158.61 | -0.8297 | -0.8297 | 0.0002 | 2.21 | 0.00007 | -- | -- | 241.07 | -28.23 | -- | -29.53 | -- | -- | -- | -389,368.50 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
Monte Rosa Therapeutics Inc | 5.76m | -130.41m | 397.70m | 103.00 | -- | 1.77 | -- | 69.06 | -2.24 | -2.24 | 0.0967 | 3.66 | 0.0185 | -- | 1.05 | 43,300.75 | -41.88 | -- | -46.47 | -- | -- | -- | -2,264.53 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
Northwest Biotherapeutics Inc | 1.65m | -75.55m | 398.06m | 25.00 | -- | -- | -- | 241.98 | -0.0644 | -0.0644 | 0.0014 | -0.047 | 0.0581 | -- | -- | 65,800.00 | -260.06 | -381.58 | -- | -- | -- | -- | -4,479.03 | -6,479.25 | -- | -14.10 | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
iTeos Therapeutics Inc | 35.00m | -108.14m | 411.24m | 157.00 | -- | 0.6194 | -- | 11.75 | -3.00 | -3.00 | 0.9517 | 18.18 | 0.0481 | -- | 1.52 | 222,929.90 | -14.86 | 5.84 | -15.55 | 7.02 | -- | -- | -308.96 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
Ginkgo Bioworks Holdings Inc | 184.34m | -897.68m | 421.13m | 1.22k | -- | 4.96 | -- | 2.28 | -18.03 | -18.03 | 3.69 | 1.62 | 0.0941 | -- | 4.20 | 151,342.40 | -45.83 | -- | -50.04 | -- | 80.22 | -- | -486.98 | -- | -- | -- | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 13.16m | 5.16% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 11.90m | 4.67% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 6.64m | 2.61% |
Geode Capital Management LLCas of 30 Jun 2024 | 4.01m | 1.57% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.72m | 1.46% |
Opaleye Management, Inc.as of 31 Mar 2024 | 3.36m | 1.32% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 2.77m | 1.09% |
Millennium Management LLCas of 31 Mar 2024 | 2.04m | 0.80% |
MIC Capital Management UK LLPas of 31 Mar 2024 | 1.74m | 0.68% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 1.44m | 0.56% |